Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 581

1.

Disease Activity, ANCA-Type, and Lipid Levels in ANCA-Associated Vasculitis.

Wallace ZS, Fu X, Liao K, Kallenberg CGM, Langford CA, Merkel PA, Monach P, Seo P, Specks U, Spiera R, St Clair EW, Zhang Y, Choi H, Stone JH.

Arthritis Rheumatol. 2019 Jun 4. doi: 10.1002/art.41006. [Epub ahead of print]

PMID:
31162829
2.

The net effect of ANCA on neutrophil extracellular trap formation.

Heeringa P, Rutgers A, Kallenberg CGM.

Kidney Int. 2018 Jul;94(1):14-16. doi: 10.1016/j.kint.2018.03.010.

PMID:
29933842
3.

Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Berti A, Warner R, Johnson K, Cornec D, Schroeder D, Kabat B, Langford CA, Hoffman GS, Fervenza FC, Kallenberg CGM, Seo P, Spiera R, St Clair EW, Brunetta P, Stone JH, Merkel PA, Specks U, Monach PA; RAVE-ITN Research Group.

Arthritis Rheumatol. 2018 Jul;70(7):1114-1121. doi: 10.1002/art.40471. Epub 2018 May 7.

PMID:
29693324
4.

Combined brain and heart magnetic resonance imaging in systemic vasculitides: fiction or real need?

Mavrogeni S, Kitas GD, Lamb HJ, Psychogios K, Dimitroulas T, Koutsogeorgopoulou L, Boki K, Vartela V, Kolovou G, Markousis-Mavrogenis G, Kallenberg CG, Guillevin L, Vassilopoulos D.

Clin Exp Rheumatol. 2018 Mar-Apr;36 Suppl 111(2):152-159. Epub 2018 Apr 10. Review.

5.

Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?

van der Geest KSM, Sandovici M, van Sleen Y, Sanders JS, Bos NA, Abdulahad WH, Stegeman CA, Heeringa P, Rutgers A, Kallenberg CGM, Boots AMH, Brouwer E.

Arthritis Rheumatol. 2018 Sep;70(9):1366-1376. doi: 10.1002/art.40520. Epub 2018 Jul 30. Review.

6.

The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis.

Rhee RL, Davis JC, Ding L, Fervenza FC, Hoffman GS, Kallenberg CGM, Langford CA, McCune WJ, Monach PA, Seo P, Spiera R, St Clair EW, Specks U, Stone JH, Merkel PA.

Clin J Am Soc Nephrol. 2018 Feb 7;13(2):251-257. doi: 10.2215/CJN.04160417. Epub 2018 Jan 25.

7.

Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.

Cornec D, Kabat BF, Mills JR, Cheu M, Hummel AM, Schroeder DR, Cascino MD, Brunetta P, Murray DL, Snyder MR, Fervenza F, Hoffman GS, Kallenberg CGM, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Stone JH, Barnidge DR, Specks U.

Rheumatology (Oxford). 2018 Apr 1;57(4):639-650. doi: 10.1093/rheumatology/kex484.

8.

Towards precision medicine in ANCA-associated vasculitis.

van der Geest KSM, Brouwer E, Sanders JS, Sandovici M, Bos NA, Boots AMH, Abdulahad WH, Stegeman CA, Kallenberg CGM, Heeringa P, Rutgers A.

Rheumatology (Oxford). 2018 Aug 1;57(8):1332-1339. doi: 10.1093/rheumatology/kex367. Review.

PMID:
29045715
9.

Genetic loci of Staphylococcus aureus associated with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides.

Glasner C, de Goffau MC, van Timmeren MM, Schulze ML, Jansen B, Tavakol M, van Wamel WJB, Stegeman CA, Kallenberg CGM, Arends JP, Rossen JW, Heeringa P, van Dijl JM.

Sci Rep. 2017 Sep 22;7(1):12211. doi: 10.1038/s41598-017-12450-z.

10.

The BVAS is an independent predictor of cardiovascular events and cardiovascular disease-related mortality in patients with ANCA-associated vasculitis: A study of 504 cases in a single Chinese center.

Bai YH, Li ZY, Chang DY, Chen M, Kallenberg CG, Zhao MH.

Semin Arthritis Rheum. 2018 Feb;47(4):524-529. doi: 10.1016/j.semarthrit.2017.07.004. Epub 2017 Aug 31.

PMID:
28917713
11.

Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis.

Bossuyt X, Cohen Tervaert JW, Arimura Y, Blockmans D, Flores-Suárez LF, Guillevin L, Hellmich B, Jayne D, Jennette JC, Kallenberg CGM, Moiseev S, Novikov P, Radice A, Savige JA, Sinico RA, Specks U, van Paassen P, Zhao MH, Rasmussen N, Damoiseaux J, Csernok E.

Nat Rev Rheumatol. 2017 Nov;13(11):683-692. doi: 10.1038/nrrheum.2017.140. Epub 2017 Sep 14. Review.

PMID:
28905856
12.

Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis.

Geetha D, Sethi S, De Vriese AS, Specks U, Kallenberg CGM, Lim N, Spiera R, St Clair EW, Merkel PA, Seo P, Monach PA, Lepori N, Fessler BJ, Langford CA, Hoffman GS, Sharma R, Stone JH, Fervenza FC; RAVE-ITN Research Group.

Am J Nephrol. 2017;46(3):231-238. doi: 10.1159/000480443. Epub 2017 Sep 8.

PMID:
28881339
13.

Are cytokines and chemokines suitable biomarkers for Takayasu arteritis?

Savioli B, Abdulahad WH, Brouwer E, Kallenberg CGM, de Souza AWS.

Autoimmun Rev. 2017 Oct;16(10):1071-1078. doi: 10.1016/j.autrev.2017.07.023. Epub 2017 Aug 2. Review.

PMID:
28778711
14.

Transancestral mapping and genetic load in systemic lupus erythematosus.

Langefeld CD, Ainsworth HC, Cunninghame Graham DS, Kelly JA, Comeau ME, Marion MC, Howard TD, Ramos PS, Croker JA, Morris DL, Sandling JK, Almlöf JC, Acevedo-Vásquez EM, Alarcón GS, Babini AM, Baca V, Bengtsson AA, Berbotto GA, Bijl M, Brown EE, Brunner HI, Cardiel MH, Catoggio L, Cervera R, Cucho-Venegas JM, Dahlqvist SR, D'Alfonso S, Da Silva BM, de la Rúa Figueroa I, Doria A, Edberg JC, Endreffy E, Esquivel-Valerio JA, Fortin PR, Freedman BI, Frostegård J, García MA, de la Torre IG, Gilkeson GS, Gladman DD, Gunnarsson I, Guthridge JM, Huggins JL, James JA, Kallenberg CGM, Kamen DL, Karp DR, Kaufman KM, Kottyan LC, Kovács L, Laustrup H, Lauwerys BR, Li QZ, Maradiaga-Ceceña MA, Martín J, McCune JM, McWilliams DR, Merrill JT, Miranda P, Moctezuma JF, Nath SK, Niewold TB, Orozco L, Ortego-Centeno N, Petri M, Pineau CA, Pons-Estel BA, Pope J, Raj P, Ramsey-Goldman R, Reveille JD, Russell LP, Sabio JM, Aguilar-Salinas CA, Scherbarth HR, Scorza R, Seldin MF, Sjöwall C, Svenungsson E, Thompson SD, Toloza SMA, Truedsson L, Tusié-Luna T, Vasconcelos C, Vilá LM, Wallace DJ, Weisman MH, Wither JE, Bhangale T, Oksenberg JR, Rioux JD, Gregersen PK, Syvänen AC, Rönnblom L, Criswell LA, Jacob CO, Sivils KL, Tsao BP, Schanberg LE, Behrens TW, Silverman ED, Alarcón-Riquelme ME, Kimberly RP, Harley JB, Wakeland EK, Graham RR, Gaffney PM, Vyse TJ.

Nat Commun. 2017 Jul 17;8:16021. doi: 10.1038/ncomms16021.

15.

M2 macrophage is the predominant phenotype in airways inflammatory lesions in patients with granulomatosis with polyangiitis.

de Souza AWS, van Timmeren M, Sanders JS, Stegeman C, Heeringa P, Kallenberg CGM, Westra J.

Arthritis Res Ther. 2017 May 18;19(1):100. doi: 10.1186/s13075-017-1310-4.

16.

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.

Clain JM, Hummel AM, Stone JH, Fervenza FC, Hoffman GS, Kallenberg CG, Langford CA, McCune WJ, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Ytterberg SR, Specks U; WGET and RAVE-ITN Research Groups.

Clin Exp Immunol. 2017 Apr;188(1):174-181. doi: 10.1111/cei.12925. Epub 2017 Feb 7.

17.

Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Wallace ZS, Miloslavsky EM, Cascino M, Unizony SH, Lu N, Hoffman GS, Kallenberg CGM, Langford CA, Merkel PA, Monach PA, Seo P, Spiera R, St Clair EW, Specks U, Brunetta P, Choi HK, Stone JH.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):1004-1010. doi: 10.1002/acr.23099.

18.

The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Cartin-Ceba R, Indrakanti D, Specks U, Stone JH, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Spiera RF, Monach PA, St Clair EW, Seo P, Tchao NK, Ytterberg SR, Brunetta PG, Song H, Birmingham D, Rovin BH; RAVE-Immune Tolerance Network Research Group.

Arthritis Rheumatol. 2017 Jan;69(1):169-175. doi: 10.1002/art.39822.

19.

Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Pepper RJ, Draibe JB, Caplin B, Fervenza FC, Hoffman GS, Kallenberg CG, Langford CA, Monach PA, Seo P, Spiera R, William St Clair E, Tchao NK, Stone JH, Specks U, Merkel PA, Salama AD; RAVE-Immune Tolerance Network Research Group.

Arthritis Rheumatol. 2017 Jan;69(1):185-193. doi: 10.1002/art.39814.

20.

Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets.

Miloslavsky EM, Lu N, Unizony S, Choi HK, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Fervenza F, Monach PA, Specks U, Stone JH.

Arthritis Rheumatol. 2016 Dec;68(12):2945-2952. doi: 10.1002/art.39812.

21.

Opponent's comments.

Kallenberg CG.

Nephrol Dial Transplant. 2016 Jul;31(7):1057-8. doi: 10.1093/ndt/gfw068a. Review. No abstract available.

PMID:
27334843
22.

Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.

Sanders JS, de Joode AA, DeSevaux RG, Broekroelofs J, Voskuyl AE, van Paassen P, Kallenberg CG, Tervaert JW, Stegeman CA.

Nephrol Dial Transplant. 2016 Sep;31(9):1453-9. doi: 10.1093/ndt/gfw211. Epub 2016 May 30.

PMID:
27242368
23.

Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis.

Mills JR, Cornec D, Dasari S, Ladwig PM, Hummel AM, Cheu M, Murray DL, Willrich MA, Snyder MR, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Stone JH, Specks U, Barnidge DR.

Anal Chem. 2016 Jun 21;88(12):6317-25. doi: 10.1021/acs.analchem.6b00544. Epub 2016 Jun 3.

24.

Pro: Cyclophosphamide in lupus nephritis.

Kallenberg CG.

Nephrol Dial Transplant. 2016 Jul;31(7):1047-52. doi: 10.1093/ndt/gfw069. Epub 2016 May 14.

PMID:
27190359
25.

Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.

Fussner LA, Hummel AM, Schroeder DR, Silva F, Cartin-Ceba R, Snyder MR, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, William St Clair E, Tchao NK, Stone JH, Specks U; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.

Arthritis Rheumatol. 2016 Jul;68(7):1700-10. doi: 10.1002/art.39637.

26.

FSAP-mediated nucleosome release from late apoptotic cells is inhibited by autoantibodies present in SLE.

Marsman G, Stephan F, de Leeuw K, Bulder I, Ruinard JT, de Jong J, Westra J, Bultink IE, Voskuyl AE, Aarden LA, Luken BM, Kallenberg CG, Zeerleder S.

Eur J Immunol. 2016 Mar;46(3):762-71. doi: 10.1002/eji.201546010. Epub 2015 Dec 22.

27.

Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.

Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CM, St Clair EW, Ikle D, Tchao NK, Ding L, Brunetta P, Choi HK, Monach PA, Fervenza F, Stone JH, Specks U; RAVE-ITN Research Group.

Ann Rheum Dis. 2016 Jun;75(6):1166-9. doi: 10.1136/annrheumdis-2015-208073. Epub 2015 Nov 30.

28.

Usefulness of antineutrophil cytoplasmic autoantibodies in diagnosing and managing systemic vasculitis.

Kallenberg CG.

Curr Opin Rheumatol. 2016 Jan;28(1):8-14. doi: 10.1097/BOR.0000000000000233. Review.

PMID:
26599378
29.

Complement system activation in ANCA vasculitis: A translational success story?

Kallenberg CG, Heeringa P.

Mol Immunol. 2015 Nov;68(1):53-6. doi: 10.1016/j.molimm.2015.06.005. Review.

PMID:
26597208
30.

Pathogenesis and treatment of ANCA-associated vasculitides.

Kallenberg CG.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 92):S11-4. Epub 2015 Oct 12. Review.

PMID:
26457917
31.

Toll-like receptor 9 activation enhances B cell activating factor and interleukin-21 induced anti-proteinase 3 autoantibody production in vitro.

Lepse N, Land J, Rutgers A, Kallenberg CG, Stegeman CA, Abdulahad WH, Heeringa P.

Rheumatology (Oxford). 2016 Jan;55(1):162-72. doi: 10.1093/rheumatology/kev293. Epub 2015 Aug 28.

PMID:
26320128
32.

Emerging role of high mobility group box 1 in ANCA-associated vasculitis.

Wang C, de Souza AW, Westra J, Bijl M, Chen M, Zhao MH, Kallenberg CG.

Autoimmun Rev. 2015 Nov;14(11):1057-65. doi: 10.1016/j.autrev.2015.07.010. Epub 2015 Jul 22. Review.

PMID:
26209906
33.

High mobility group box 1 serum levels are increased in Behçet's disease, but not associated with disease activity or disease manifestations.

de Souza AW, Perazzio SF, de França NR, Andrade LE, Bijl M, Westra J, Kallenberg CG.

Rheumatology (Oxford). 2015 Dec;54(12):2151-5. doi: 10.1093/rheumatology/kev202. Epub 2015 Jul 12.

PMID:
26170374
34.

High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins.

de Souza AW, van der Geest KS, Brouwer E, Pinheiro FA, Oliveira AC, Sato EI, Andrade LE, Bijl M, Westra J, Kallenberg CG.

Arthritis Res Ther. 2015 Jun 12;17:158. doi: 10.1186/s13075-015-0672-8.

35.

Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Grayson PC, Carmona-Rivera C, Xu L, Lim N, Gao Z, Asare AL, Specks U, Stone JH, Seo P, Spiera RF, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Ytterberg SR, Phippard DJ, Merkel PA, Kaplan MJ, Monach PA; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.

Arthritis Rheumatol. 2015 Jul;67(7):1922-32. doi: 10.1002/art.39153.

36.

Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.

Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Ding L, Iklé D, Villareal M, Lim N, Brunetta P, Fervenza FC, Monach PA, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.

Arthritis Rheumatol. 2015 Jun;67(6):1629-36. doi: 10.1002/art.39104.

37.

B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.

Kallenberg CG, Hauser T.

Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i119-22. doi: 10.1093/ndt/gfv056. Epub 2015 Mar 9. Review.

PMID:
25753806
38.

Low anti-staphylococcal IgG responses in granulomatosis with polyangiitis patients despite long-term Staphylococcus aureus exposure.

Glasner C, van Timmeren MM, Stobernack T, Omansen TF, Raangs EC, Rossen JW, de Goffau MC, Arends JP, Kampinga GA, Koedijk DG, Neef J, Buist G, Tavakol M, van Wamel WJ, Rutgers A, Stegeman CA, Kallenberg CG, Heeringa P, van Dijl JM.

Sci Rep. 2015 Feb 2;5:8188. doi: 10.1038/srep08188.

39.

Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients?

de Groot L, Jager NA, Westra J, Smit AJ, Kallenberg CG, Posthumus MD, Bijl M.

Rheumatology (Oxford). 2015 Jul;54(7):1257-61. doi: 10.1093/rheumatology/keu459. Epub 2015 Jan 12.

PMID:
25587178
40.

Ig gene analysis reveals altered selective pressures on Ig-producing cells in parotid glands of primary Sjögren's syndrome patients.

Hamza N, Hershberg U, Kallenberg CG, Vissink A, Spijkervet FK, Bootsma H, Kroese FG, Bos NA.

J Immunol. 2015 Jan 15;194(2):514-21. doi: 10.4049/jimmunol.1302644. Epub 2014 Dec 8.

41.

Clinical immunology--autoimmunity in the Netherlands.

Tervaert JW, Kallenberg CG.

Immunol Lett. 2014 Dec;162(2 Pt B):134-40. doi: 10.1016/j.imlet.2014.10.008. Epub 2014 Oct 18. Review.

PMID:
25455600
42.

Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis and potential targets for biologic treatment.

Sanders JS, Abdulahad WH, Stegeman CA, Kallenberg CG.

Nephron Clin Pract. 2014;128(3-4):216-23. doi: 10.1159/000368570. Epub 2014 Nov 11. Review.

43.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.

Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Tchao NK, Ikle D, Jepson B, Brunetta P, Fervenza FC; Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group.

J Am Soc Nephrol. 2015 Apr;26(4):976-85. doi: 10.1681/ASN.2014010046. Epub 2014 Nov 7.

44.

Advances in pathogenesis and treatment of ANCA-associated vasculitis.

Kallenberg CG.

Discov Med. 2014 Oct;18(99):195-201. Review.

45.

Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.

Unizony S, Lim N, Phippard DJ, Carey VJ, Miloslavsky EM, Tchao NK, Iklé D, Asare AL, Merkel PA, Monach PA, Seo P, St Clair EW, Langford CA, Spiera R, Hoffman GS, Kallenberg CG, Specks U, Stone JH.

Arthritis Rheumatol. 2015 Feb;67(2):535-44. doi: 10.1002/art.38916.

46.

Response to ‘T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?’.

Dolff S, Abdulahad WH, Kallenberg CG.

Arthritis Res Ther. 2014;16(3):409. No abstract available.

47.

Are urinary levels of high mobility group box 1 markers of active nephritis in anti-neutrophil cytoplasmic antibody-associated vasculitis?

de Souza AW, Abdulahad WH, Sosicka P, Bijzet J, Limburg PC, Stegeman CA, Bijl M, Westra J, Kallenberg CG.

Clin Exp Immunol. 2014 Nov;178(2):270-8. doi: 10.1111/cei.12422.

48.

Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.

Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Viviano L, Ding L, Iklé D, Villarreal M, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.

Arthritis Rheumatol. 2014 Nov;66(11):3151-9. doi: 10.1002/art.38788.

49.

Key advances in the clinical approach to ANCA-associated vasculitis.

Kallenberg CG.

Nat Rev Rheumatol. 2014 Aug;10(8):484-93. doi: 10.1038/nrrheum.2014.104. Epub 2014 Jul 1. Review.

PMID:
24980139
50.

Differential expression of granulopoiesis related genes in neutrophil subsets distinguished by membrane expression of CD177.

Hu N, Mora-Jensen H, Theilgaard-Mönch K, Doornbos-van der Meer B, Huitema MG, Stegeman CA, Heeringa P, Kallenberg CG, Westra J.

PLoS One. 2014 Jun 13;9(6):e99671. doi: 10.1371/journal.pone.0099671. eCollection 2014.

Supplemental Content

Loading ...
Support Center